BACKGROUND: BK polyomavirus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT). Little is known about the host immune response, effectiveness of antiviral treatment, or impact of asymptomatic replication on long-term kidney function. METHODS: In children and young adults undergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1-4, 8, 12, and 24 post-HCT) and tested associations of peak viremia ≥10 000 or viruria ≥109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant. We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T cells by enzyme-linked immune absorbent spot at Month 3 and cidofovir use. RESULTS: We prospectively enrolled 193 participants (median age 10 years) and found that 18% had viremia ≥10 000 copies/mL and 45% had viruria ≥109 copies/mL in the first 3 months post-HCT. Among the 147 participants without cystitis (asymptomatic), 58 (40%) had any viremia. In the entire cohort and asymptomatic subset, having viremia ≥10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT. Viremia ≥10 000 copies/mL was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1-4.2). Clearing viremia was associated with detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure. CONCLUSIONS: Screening for BKPyV viremia after HCT identifies asymptomatic patients at risk for kidney disease and reduced survival. These data suggest potential changes to clinical practice, including prospective monitoring for BKPyV viremia to test virus-specific T cells to prevent or treat BKPyV replication.
BACKGROUND:BK polyomavirus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT). Little is known about the host immune response, effectiveness of antiviral treatment, or impact of asymptomatic replication on long-term kidney function. METHODS: In children and young adults undergoing allogeneic HCT, we quantified BKPyVviruria and viremia (pre-HCT and at Months 1-4, 8, 12, and 24 post-HCT) and tested associations of peak viremia ≥10 000 or viruria ≥109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant. We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T cells by enzyme-linked immune absorbent spot at Month 3 and cidofovir use. RESULTS: We prospectively enrolled 193 participants (median age 10 years) and found that 18% had viremia ≥10 000 copies/mL and 45% had viruria ≥109 copies/mL in the first 3 months post-HCT. Among the 147 participants without cystitis (asymptomatic), 58 (40%) had any viremia. In the entire cohort and asymptomatic subset, having viremia ≥10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT. Viremia ≥10 000 copies/mL was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1-4.2). Clearing viremia was associated with detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure. CONCLUSIONS: Screening for BKPyVviremia after HCT identifies asymptomatic patients at risk for kidney disease and reduced survival. These data suggest potential changes to clinical practice, including prospective monitoring for BKPyVviremia to test virus-specific T cells to prevent or treat BKPyV replication.
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: Rima M Saliba; Katayoun Rezvani; Ann Leen; Jeffrey Jorgensen; Nina Shah; Chitra Hosing; Simrit Parmar; Betul Oran; Amanda Olson; Gabriela Rondon; Julianne Chen; Charles Martinez; Amir Hamdi; Rohtesh S Mehta; Roy F Chemaly; Ila M Saunders; Catherine M Bollard; Elizabeth J Shpall Journal: Biol Blood Marrow Transplant Date: 2015-02-20 Impact factor: 5.742
Authors: Hilary L Haines; Benjamin L Laskin; Jens Goebel; Stella M Davies; Hong J Yin; Julia Lawrence; Parinda A Mehta; Jack J Bleesing; Alexandra H Filipovich; Rebecca A Marsh; Sonata Jodele Journal: Biol Blood Marrow Transplant Date: 2011-03-06 Impact factor: 5.742
Authors: Anastasia Papadopoulou; Ulrike Gerdemann; Usha L Katari; Ifigenia Tzannou; Hao Liu; Caridad Martinez; Kathryn Leung; George Carrum; Adrian P Gee; Juan F Vera; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen Journal: Sci Transl Med Date: 2014-06-25 Impact factor: 17.956
Authors: F Ginevri; A Azzi; H H Hirsch; S Basso; I Fontana; M Cioni; S Bodaghi; V Salotti; A Rinieri; G Botti; F Perfumo; F Locatelli; P Comoli Journal: Am J Transplant Date: 2007-10-01 Impact factor: 8.086
Authors: Hans H Hirsch; Wendy Knowles; Michael Dickenmann; Jakob Passweg; Thomas Klimkait; Michael J Mihatsch; Jürg Steiger Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544
Authors: Joanna M Schaenman; Yael Korin; Tiffany Sidwell; Fadi Kandarian; Nicholas Harre; David Gjertson; Erik L Lum; Uttam Reddy; Edmund Huang; Phuong T Pham; Suphamai Bunnapradist; Gabriel M Danovitch; Jefferey Veale; H Albin Gritsch; Elaine F Reed Journal: Transplantation Date: 2017-06 Impact factor: 5.385
Authors: Jeremy D Rubinstein; Xiang Zhu; Carolyn Lutzko; Tom Leemhuis; Jose A Cancelas; Sonata Jodele; Catherine M Bollard; Patrick J Hanley; Stella M Davies; Michael S Grimley; Adam S Nelson Journal: Blood Adv Date: 2020-07-28
Authors: Hannah Imlay; Hu Xie; Wendy M Leisenring; Elizabeth R Duke; Louise E Kimball; Meei-Li Huang; Steven A Pergam; Joshua A Hill; Keith R Jerome; Filippo Milano; W Garrett Nichols; Phillip S Pang; Hans H Hirsch; Ajit P Limaye; Michael Boeckh Journal: Blood Adv Date: 2020-02-25
Authors: Elizabeth A Odegard; Heidi L Meeds; Steven B Kleiboeker; Assem Ziady; Anthony Sabulski; Sonata Jodele; Alix E Seif; Stella M Davies; Benjamin L Laskin; Jason T Blackard Journal: J Virol Methods Date: 2021-10-07 Impact factor: 2.014
Authors: Sonata Jodele; Christopher E Dandoy; Anthony Sabulski; Jane Koo; Adam Lane; Kasiani C Myers; Gregory Wallace; Ranjit S Chima; Ashley Teusink-Cross; Russel Hirsch; Thomas D Ryan; Stefanie Benoit; Stella M Davies Journal: Transplant Cell Ther Date: 2022-04-29
Authors: Elizabeth A Odegard; Heidi L Meeds; Steven B Kleiboeker; Assem Ziady; Anthony Sabulski; Sonata Jodele; Alix E Seif; Stella M Davies; Benjamin L Laskin; Jason T Blackard Journal: Microbiol Resour Announc Date: 2022-01-06
Authors: Sonata Jodele; Mario Medvedovic; Nathan Luebbering; Jenny Chen; Christopher E Dandoy; Benjamin L Laskin; Stella M Davies Journal: Blood Adv Date: 2020-03-24
Authors: Elizabeth M Holland; Corina Gonzalez; Elliot Levy; Vladimir A Valera; Heather Chalfin; Jacquelyn Klicka-Skeels; Bonnie Yates; David E Kleiner; Colleen Hadigan; Hema Dave; Haneen Shalabi; Dennis D Hickstein; Helen C Su; Michael Grimley; Alexandra F Freeman; Nirali N Shah Journal: Front Immunol Date: 2021-12-17 Impact factor: 7.561
Authors: Adam S Nelson; Daria Heyenbruch; Jeremy D Rubinstein; Anthony Sabulski; Sonata Jodele; Shawn Thomas; Carolyn Lutzko; Xiang Zhu; Thomas Leemhuis; Jose A Cancelas; Michael Keller; Catherine M Bollard; Patrick J Hanley; Stella M Davies; Michael S Grimley Journal: Blood Adv Date: 2020-11-24